Evidence map›Paper›PMID 42626783›Full record

ArticleCirculation research2026

FPR1-Driven Neutrophil-Endothelial Cell Axis Promotes Angiogenesis in PAOD.

Fengyang Li, Peishen Zhao, Tianshu Wei, Yuqin Zha, Xinhao Zhao, Owen L Woodman, Yuguo Chen, Xiaojun Zhou, Cheng Xue Qin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fengyang LiState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Shandong University, Jinan, China (F.L., Y.Z., X. Zhou, C.X.Q.).
Peishen ZhaoDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.Z., O.L.W.).ORCID 0000-0003-0185-0595
Tianshu WeiDepartment of Endocrinology and Metabology, Shandong Provincial Key Medical and Health Laboratory of Translational Medicine in Microvascular Aging, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China (T.W., X. Zhou).ORCID 0000-0002-7494-8609
Yuqin ZhaState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Shandong University, Jinan, China (F.L., Y.Z., X. Zhou, C.X.Q.).
Xinhao ZhaoDepartment of Gastroenterology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China (X. Zhao).
Owen L WoodmanDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (P.Z., O.L.W.).ORCID 0000-0003-3759-1396
Yuguo Chen *Department of Emergency Medicine, Qilu Hospital, Shandong University, Jinan, China (F.L., Y.C., C.X.Q.).ORCID 0000-0001-9501-2546
Xiaojun Zhou *State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Shandong University, Jinan, China (F.L., Y.Z., X. Zhou, C.X.Q.).
Cheng Xue Qin *State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Shandong University, Jinan, China (F.L., Y.Z., X. Zhou, C.X.Q.).ORCID 0000-0003-2169-2686

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeripheral artery occlusive disease (PAOD) is characterized by limb ischemia, heightened inflammation, and a substantial risk of mortality and amputation. Coordinated regulation of inflammation resolution and angiogenesis represents a promising therapeutic strategy. Given the established roles of FPRs (formyl peptide receptors) in inflammation resolution, we investigated their contribution to the integrated control of inflammation and angiogenesis in PAOD.

methodsUsing a murine hindlimb ischemia model and clinical blood samples, we identified FPR1 as a key regulator of PAOD. We evaluated hindlimb perfusion recovery and inflammatory responses in

resultsWe identified FPR1 as a pivotal regulator in PAOD.

conclusionsFPR1 is a central regulator of inflammation and angiogenesis in PAOD. Biased FPR1 activation engages a neutrophil/CCL2-endothelial/HMOX1 axis to resolve inflammation and promote angiogenesis, supporting its therapeutic potential in PAOD.

Indexed as

Endothelial CellsNeovascularization, PhysiologicNeutrophilsReceptors, Formyl PeptideAnimalsCells, CulturedChemokine CCL2Disease Models, AnimalHeme Oxygenase-1HindlimbHumansHuman Umbilical Vein Endothelial CellsIschemiaMaleMiceMice, Inbred C57BLCcl2 protein, mouseChemokine CCL2FPR1 protein, humanFpr1 protein, mouseHeme Oxygenase-1Receptors, Formyl PeptideVascular Endothelial Growth Factor Aangiogenesischemokine CCL2endothelial cellsheme oxygenase-1neutrophilsreceptors, formyl peptide

Identifiers

PMID42626783
PMCPMC13608278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.